OBJECTIVE： To observe clinical efficacy and safety of entecavir in adjunctive treatment of hepatitis B secondary liver cancer during perioperative period of transcatheter arterial chemoembolization （TACE）. METHODS： 130 patients from our hospital during Jun. 2012 to Jun. 2013 with hepatitis B secondary liver cancer undergoing TACE were selected and divided into control group and observation group according to random number table， with 65 cases in each group. Control group received TACE. Fluorouracil injection 20 mL+Epirubicin hydrochloride injection 10 mL added into 0.9％ Sodium chloride injection 500 mL， ivgtt. Observation group was given Entecavir maleate tablet 0.5 mg， po， qd， since 1 week before TACE， for 12 months. Clinical efficacy， the levels of AFP， ALT and HBV-DNA， daily life quality score and survival rate were observed in 2 groups， and the occurrence of ADR was recorded. RESULTS： Before treatment， there was no statistical significance in the levels of AFP， HBV-DNA and ALT， daily life quality score between 2 groups （P＞0.05）. After treatment， total effective rate of observation group was significantly higher than that of control group （41.54％ vs. 20.00％）， the levels of AFP， HBV-DNA and ALT in observation group were significantly lower than in control group， daily life quality score of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. The survival rate of 1， 2， 3 years follow-up in observation group were significantly higher than control group （75.38％ vs. 52.31％、53.85％ vs. 29.23％、32.31％ vs. 15.38％， respectively）， with statistically significance （P＜0.05）. There was no significant difference in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS： For patients with hepatitis B secondary liver cancer， entecavir adjunctive treatment of during perioperative period of TACE can effectively control disease progression， protects the liver function， improves the quality of daily life and is helpful to extend the overall survival rate with good safety.